MedPath

the Role of Repetitive Trans Cranial-magnetic Stimulation in Craving Reduction Among Opioid Use Disorder Patients

Not Applicable
Conditions
Substance Use Disorders
Interventions
Device: repetitive trans magnetic stimulation
Registration Number
NCT04691167
Lead Sponsor
Ain Shams University
Brief Summary

Repetitive Trans-cranial Magnetic Stimulation (rTMS) is a relatively safe and non-invasive method to modulate neuronal activity; rTMS uses alternating magnetic fields in a certain frequency to induce an electric current in the underlying brain tissue.

Administering high frequency rTMS to the left dorsolateral prefrontal cortex is possible to increase brain activity in the stimulated area and to change brain activity in associated regions that are part of the same neural circuit which may reduce craving.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
52
Inclusion Criteria
  1. Age range: 18-45 years old
  2. Gender: males
  3. Opioid Use disorder according to the DSM-5 (early abstinence starting 1 week up to 1 month).
Read More
Exclusion Criteria
  1. Presence of other serious mental illness (e.g.; psychotic disorders, bipolar affective disorder, depression with psychotic features).
  2. Patients with any other serious medical illness.
  3. Previous treatment with repetitive Trans- cranial magnetic stimulation.
  4. Patients with contraindications to rTMS as cardiac patient with pacemaker.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
group 2, sham controlled grouprepetitive trans magnetic stimulation-
group 1, Active intervention grouprepetitive trans magnetic stimulation-
Primary Outcome Measures
NameTimeMethod
craving severity6 weeks

measure severity of drug craving using craving severity scale, the scale is called brief substance craving scale. a higher outcome is a worse result

heroin craving6 weeks

using the heroin craving questionnaire, a higher score indicates a worse outcome

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath